Literature DB >> 9952261

The EEG and prognosis in status epilepticus.

M Nei1, J M Lee, V L Shanker, M R Sperling.   

Abstract

PURPOSE: To examine the relation between specific EEG features and clinical outcome, determine whether a predictable sequence of EEG patterns exists during status epilepticus (SE), and examine the relation between periodic epileptiform discharges (PEDs) and SE.
METHODS: EEG records of 50 patients with SE admitted to Graduate Hospital between January 1990 and July 1995 were reviewed. Ictal EEGs were available in 72%; 28% had only postictal EEGs. Poor outcome was defined as death or persistent vegetative state, and good outcome as all others. Fisher's Exact test, chi2, and t tests were performed for data analysis.
RESULTS: Of 50 patients, 72% had a good outcome and 28%, a poor outcome. If PEDs were present at any time during or after SE, outcome tended to be worse (p = 0.053). With PEDs, eight (44%) of 18 had a poor outcome; without PEDs, six (19%) of 32 had a poor outcome. Etiologies for SE did not substantially differ in patients with or without PEDs, and structural abnormalities were not more associated with the presence of PEDs. PEDs were seen both early and late, during and after SE. Other EEG characteristics (lateralized vs. bilateral symmetric ictal EEG, discrete vs. continuous ictal activity, and postictal focal slowing) did not relate to outcome. No predictable sequence of EEG changes was found during SE.
CONCLUSIONS: PEDs are the only EEG feature related to outcome in SE and are associated with poor outcome independent of etiology.

Entities:  

Mesh:

Year:  1999        PMID: 9952261     DOI: 10.1111/j.1528-1157.1999.tb02069.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  19 in total

1.  Mortality Associated with Status Epilepticus.

Authors:  Jane G. Boggs
Journal:  Epilepsy Curr       Date:  2004-01       Impact factor: 7.500

Review 2.  Modern electroencephalography.

Authors:  Robin Kennett
Journal:  J Neurol       Date:  2012-04       Impact factor: 4.849

Review 3.  Continuous electroencephalogram monitoring in the critically ill.

Authors:  John J Wittman; Lawrence J Hirsch
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 4.  EEG in the diagnosis, classification, and management of patients with epilepsy.

Authors:  S J M Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

5.  Prognostic significance of continuous EEG monitoring in patients with poor-grade subarachnoid hemorrhage.

Authors:  Jan Claassen; Lawrence J Hirsch; Jennifer A Frontera; Andres Fernandez; Michael Schmidt; Gregory Kapinos; John Wittman; E Sander Connolly; Ronald G Emerson; Stephan A Mayer
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 6.  The Ictal-Interictal Continuum: To Treat or Not to Treat (and How)?

Authors:  Clio Rubinos; Alexandra S Reynolds; Jan Claassen
Journal:  Neurocrit Care       Date:  2018-08       Impact factor: 3.210

7.  The role of cEEG as a predictor of patient outcome and survival in patients with intraparenchymal hemorrhages.

Authors:  Mallika Purandare; Alexa N Ehlert; Henri Vaitkevicius; Barbara A Dworetzky; Jong Woo Lee
Journal:  Seizure       Date:  2018-08-15       Impact factor: 3.184

Review 8.  Treatment of Refractory and Super-refractory Status Epilepticus.

Authors:  Samhitha Rai; Frank W Drislane
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

Review 9.  Recent developments in the diagnosis and treatment of status epilepticus.

Authors:  Megan Selvitelli; Frank W Drislane
Journal:  Curr Neurol Neurosci Rep       Date:  2007-11       Impact factor: 5.081

10.  Generalized periodic discharges in the critically ill: a case-control study of 200 patients.

Authors:  Brandon Foreman; Jan Claassen; Karine Abou Khaled; Jeffrey Jirsch; Daniel M Alschuler; John Wittman; Ronald G Emerson; Lawrence J Hirsch
Journal:  Neurology       Date:  2012-10-03       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.